Skip to main content

Drug Price Debate May Not Hinder Biotech ETFs After All

The issue of pharmaceuticals pricing reform — a long-time favorite discussion on Capitol Hill — is gaining momentum, and some healthcare assets are bearing that burden. For example, the ALPS Medical Breakthroughs ETF (SBIO) is lower by 2.35% over the past week as investors fret about the specter of...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.